{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"086-576-810-695-150","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"086-576-810-695-150"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11617,"type":"PATENT","title":"Emory University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6117,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8292,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately:uni* AND virginia
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4231
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately:uni* AND virginia
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4231
administering to a patient in need thereof a therapeutically effective amount of an A2B adenosine receptor antagonist, wherein the A2B adenosine antagonist is a compound of formula Id or a stereoisomer or pharmaceutically acceptable salt thereof,\n\n
wherein R1 and R2 are independently selected from H, (C1-C8)alkyl, (C3-C8)alkenyl, (C3-C8)alkynyl, (C1-C8)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C8)alkyl-, (C4-C10)heterocycle, (C4-C10)heterocycle(C1-C8)alkyl-, (C6-C10)aryl, (C6-C10)aryl(C1-C8)alkyl-, (C5-C10)heteroaryl, and (C5-C10)heteroaryl(C1-C8)alkyl-;\n
R4 and R5 are independently selected from H, (C1-C8)alkyl, (C3-C8)alkenyl, (C3-C8)alkynyl, (C1-C8)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C8)alkyl-, (C6-C18)polycycloalkyl, (C6-C18)polycycloalkyl(C1-C8)alkyl-, (C3-C10)heterocycle, (C3-C10)heterocycle(C1-C8)alkyl-, —NR7R8 (C6-C10)aryl, (C6-C10)aryl(C1-C8)alkyl-, (C5-C10)heteroaryl, (C5-C10)heteroaryl(C1-C8)alkyl-,—(C2-C4—Y)q—(CH2)2-4—X1, —C(O)R6, —CO2R6, —C(O)NR7R8 and —S(O)2—NR7R8;\n
X1 is selected from —OR6, —C(O)R6, —CO2R6 and —NR7R8;\n
Y is selected from oxy (—O—), thio (—S—), sulfinyl (—SO—), sulfonyl (—S(O)2—) and amine-N(R9) —;\n
R6 is selected from H, (C1-C8)alkyl, RaO(C1-C8)alkyl, RbRcN(C1-C8)alkyl, halo(C1-C8)alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalky(C1-C4)alkyl-, (C3-C10)heterocycle, (C3-C10)heterocycle(C1-C8)alkyl-, (C6-C10)aryl, (C6-C10)aryl(C1-C8)alkyl-, (C4-C10)heteroaryl and (C4-C10)heteroaryl(C1-C8)alkyl-;\n
R7, R8 and R9 are independently selected from H, (C1-C8)alkyl, RaO(C1-C8)alkyl, RbRcN(C1-C8)alkyl, halo(C1-C8)alkyl, (C3-C10)heterocycle, (C6-C10)aryl, (C6-C10)aryl(C1-C8)alkyl-, (C4-C10)heteroaryl; —COORa, —C(O)Ra and —C(O)NRbRc;\n
alternatively, R7 and R8 together with the atoms to which they are attached, form a saturated or partially unsaturated, mono-, bicyclic- or aromatic ring having 3, 4, 5, 6, 7 or 8 ring atoms and there optionally being 1, 2, 3, or 4 heteroatoms selected from non-peroxide oxy (—O—), thio (—S—), sulfinyl (—SO—), sulfonyl (—S(O)2—) or amine —N(Rb)-in the ring;\n
wherein the alkyl, alkenyl, cycloalkyl, alkynyl, aryl, heterocycle or heteroaryl groups of R1, R2, R4, R5, R6, R7, R8 and R9 are optionally substituted with one or more substituents independently selected from halo, cyano, nitro, —ORa, —SRa, (C1-C8)alkyl, (C6-C10)aryl, —O(C6-C10)aryl, hydroxy(C1-C8)alkyl, RbRcN(C1-C8)alkyl, halo(C1-C8)alkyl, —NRbRc, —C(O)Ra, —COORa and —C(O)NRbRc;\n
Ra is selected from H, and (C1-C6)alkyl;\n
Rb and Rc are each independently selected from H, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C8)cycloalkyl, C1-C6)alkylthio, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl-, heteroaryl and heteroaryl(C1-C6)alkyl-;\n
alternatively, Rb and Rc together with the nitrogen to which they are attached, form a ring selected from pyrrolidyl, piperidyl, piperazinyl, azepinyl, diazepinyl, morpholinyl and thiomorpholinyl;\n
m is independently selected from 1 and 2; and,\n
q is independently selected from 1, 2, 3 and 4."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the compound is selected from:\n\n\n\n\n\n\n\n\n\n
and a pharmaceutically acceptable salt thereof."],"number":2,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}